Purple AI Inc.

Purple AI operates in the intersection of artificial intelligence, medical imaging, and health diagnostics, with a specific emphasis on stroke and brain-disease workflows. Its offering spans automated suspected-hemorrhage alerts, DICOM image review on mobile devices, secure hospital deployment, and clinician communication. The company’s market position is therefore best viewed as an early-stage specialist rather than an established category leader. Its Seoul base and investor group—Murex Partners, Mashup Ventures, Digital Healthcare Partners, and Big Basin Capital—place it within South Korea’s emerging digital-health ecosystem, while the TIPS Program grant adds public innovation support. The main strategic question is whether Purple AI can convert its integrated workflow into validated hospital deployments and regulatory traction. Without disclosed customer counts, approval milestones, diagnostic accuracy metrics, or commercial revenue, its competitive standing remains difficult to quantify. Its focus on rapid stroke response gives it a clear clinical use case, but execution evidence is still limited.

Purple AI has followed an early-stage funding and capability-building trajectory since its October 2024 founding. The company raised approximately $1.73 million in a February 19, 2025 seed round led by Murex Partners, joined by Mashup Ventures, Digital Healthcare Partners, and Big Basin Capital. A TIPS Program grant announced on July 29, 2025 extended its financing support, bringing the recorded round count to two and making the grant its latest funding event. The product set suggests expansion from core image analysis into a broader stroke-care workflow: Hyper Insight Suite for Deployment addresses scalable hospital operation, Suspected Case Notification supports urgent triage, Mobile DICOM Viewer enables remote access, and In-App Team Communication supports coordination. In February 2026, the addition of Joshua N. Goldstein as scientific advisor marked an important clinical-research inflection point, particularly for stroke and neurocritical-care strategy. Employee information indicates a very small organization with five listed current positions, including a CEO, two CMO listings, a CTO, and the scientific advisor. Hiring growth, revenue, customer adoption, and regulatory progress are not publicly established, so the trajectory remains promising but not yet validated at scale.